FocusCystic Fibrosis

CFTR Potentiators: Not an Open and Shut Case

See allHide authors and affiliations

Science Translational Medicine  23 Jul 2014:
Vol. 6, Issue 246, pp. 246fs27
DOI: 10.1126/scitranslmed.3009674

You are currently viewing the abstract.

View Full Text


Insights into the positive and negative effects of drugs to treat cystic fibrosis (CF) patients with a common mutation raise questions about how we discover and translate CF therapeutics (Veit et al. and Cholon et al., this issue).

View Full Text